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We investigated the interaction of the human plasma 
proteinase inhibitor heparin cofactor II (HC) with hu- 
man neutrophil elastase and cathepsin G in order to 
examine 1) proteinase inhibition by HC, 2) inactivation 
of HC, and 3) the effect of glycosaminoglycans on 
inhibition and inactivation. We found that HC inhibited 
cathepsin G, but not elastase, with a rate constant of 
6.0 X lo6 Mm1 min-‘. Inhibition was stable, with a 
dissociation rate constant of 1.0 x low3 min-‘. Heparin 
and dermatan sulfate diminished inhibition slightly. 
Both neutrophil elastase and cathepsin G at catalytic 
concentrations destroyed the thrombin inhibition ac- 
tivity of HC. Inactivation was accompanied by a dra- 
matic increase in heat stability, as occurs with other 
serine proteinase inhibitors. Proteolysis of HC (i%& 
66,000) produced a species (Mr 58,000) that retained 
thrombin inhibition activity, and an inactive species of 
M, 48,000. Amino acid sequence analysis led to the 
conclusion that both neutrophil elastase and cathepsin 
G cleave HC at Ile”, which does not affect HC activity, 
and at Va143e, near the reactive site Leu444, which 
inactivates HC. Since cathepsin G is inhibited by HC 
and also inactivates HC, we conclude that cathepsin G 
participates in both reactions simultaneously so that 
small amounts of cathepsin G can inactivate a molar 
excess of HC. High concentrations of heparin and der- 
matan sulfate accelerated inactivation of HC by neu- 
trophil proteinases, with heparin having a greater ef- 
fect. Heparin and dermatan sulfate appeared to alter 
the pattern, and not just the rate, of protelysis of HC. 
We conclude that while HC is an effective inhibitor of 
cathepsin G, it can be proteolyzed by neutrophil pro- 
teinases to generate first an active inhibitor and then 
an inactive molecule. This two-step mechanism might 
be important in the generation of chemotactic activity 
from the amino-terminal region of HC. 
During the acute inflammatory response, neutrophils re- 
spond to a variety of endogenous and exogenous stimuli by 
migrating to sites of injury and releasing substances that 
damage pathogens as well as host tissue (1). Among the 
hydrolytic enzymes released are serine proteinases. These 
enzymes are believed to be regulated in uiuo by members of 
the serine proteinase inhibitor (serpin) family of proteins. 
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Interestingly, neutrophils and their released products can also 
inactivate many serpins not only by oxidizing a critical me- 
thionine residue in a,-proteinase inhibitor (2, 3) but also by 
cleaving peptide bonds in an exposed loop near the reactive 
sites of several other serpins (5-8). The balance between 
proteinase activity and proteinase inhibition is critical; dis- 
ruption of the balance might contribute to disease states such 
as emphysema and rheumatoid arthritis. 
We are interested in the properties of the plasma proteinase 
inhibitor heparin cofactor II (HC),’ which is a member of the 
serpin family. HC, like its homologue antithrombin III, inhib- 
its thrombin in a reaction whose rate is dramatically increased 
by heparin and other glycosaminoglycans (9). This property 
suggests a potential role for thrombin inhibition by HC in 
viuo at sites rich in glycosaminoglycans, such as vessel walls 
and exposed basement membranes. The physiological impor- 
tance of HC might also depend on the production of leukocyte 
chemoattractants from the HC protein, as we recently re- 
ported (10). 
We investigated the interaction of HC with two major 
neutrophil proteinases, elastase and cathepsin G. Because HC 
is a potent inhibitor of chymotrypsin (ll), it might inhibit 
cathepsin G, which has similar hydrolytic specificity (12). On 
the other hand, neutrophil elastase, which inactivates the 
related serpins antithrombin III, az-antiplasmin, al-antichy- 
motrypsin, and Cl inhibitor (4, 5, 8), might also inactivate 
HC. Sie et al. (13) have shown that neutrophil extracts degrade 
and inactivate HC, but the degrading activity was not iden- 
tified. It is known that neutrophil elastase proteolytically 
inactivates antithrombin III in a reaction that is accelerated 
by heparin (8, 14); however, the effect of glycosaminoglycans 
on HC inactivation by purified neutrophil proteinases is not 
known. 
In this study, we found that HC inhibits cathepsin G, but 
not elastase, and that both cathepsin G and elastase inactivate 
HC by a proteolytic reaction that is accelerated by heparin 
and dermatan sulfate. Additionally, we found that the initial 
product of the reaction between HC and neutrophil protein- 
ases is a degraded form of HC that retains its inhibitory 
properties. A preliminary report has appeared in abstract form 
(15). 
EXPERIMENTAL PROCEDURES 
Materials-HC was purified from human plasma as described (16). 
HC concentrations were determined using an extinction coefficient 
of 0.59 ml mg-’ cm-’ at 280 nm (17). Human neutrophil elastase and 
cathepsin G purchased from Elastin Products (Pacific, MO) were 
assumed to be 100% active and were stored in 0.2 M sodium acetate, 
1 The abbreviations used are: HC, heparin cofactor II; SDS-PAGE, 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis; PMSF, 
phenylmethylsulfonyl fluoride; HEPES, 4-(2-hydroxyethyl)-l-piper- 
azineethanesulfonic acid. 
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pH 5.0, at -20 “C. Human cu-thrombin was purified as described (18) 
and active site-titrated with p-nitrophenyl p’guanidinobenzoate 
(Sigma) (19). Heparin was provided by Diosynth (Oss, Netherlands). 
Dermatan sulfate from Calbiochem was treated with nitrous acid to 
remove heparin contaminants (20). All experiments were performed 
in 20 mM HEPES, 150 mM sodium chloride, 0.1% polyethylene glycol 
8000, 0.1% Triton X-100, pH 7.4, at 25 “C. 
Proteinuse Inhibition-Cathepsin G activity was assayed with 0.2 
mM N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide (Sigma); neutrophil 
elastase activity was assayed with 0.2 mM methoxysuccinyl-Ala-Ala- 
Pro-Val-p-nitroanilide (Sigma). For cathepsin G, the inhibition rate 
constant. (krJ was determined under second-order conditions using 
100 nM HC and 100 nM oroteinase in a volume of 100 ~1. At various 
times from 5 to 30 s, 700 ;l of 0.3 mM substrate was added. Hydrolysis 
was terminated after 30 min with acetic acid. Absorbance at 405 nm 
was linearly related to cathepsin G concentration. The equation used 
to calculate k,, was the standard second-order rate equation: l/[Plt 
= k+,t + l/[P], where [PI! and [PI0 are proteinase concentrations at 
a time t, or at t = 0, respectively (21). Dissociation of inhibition was 
measured with the same protein concentrations in 1 ml. Aliquots of 
100 ~1 were removed at intervals of 0.5-5 h and added to 700 ~1 of 
substrate. The reaction was terminated after 30 min. The dissociation 
rate constant (k-i) was calculated using the standard first-order rate 
equation: ln[Plt/[Plo = k-,t (21). Kinetic measurements were also 
performed in the presence of 50 pg/ml heparin or 100 bg/ml dermatan 
sulfate. Experiments were performed from 2 to 5 times and the results 
averaged. 
Additional experiments with cathepsin G inhibition involved 500 
nM HC and 500 nM cathensin G in 400 ul. Aliouots of 70 ul were 
removed at intervals of lo-50 s and added to 100 ;l of substrate. The 
reaction was stopped after 15 min by the addition of 25 ~1 of 50% 
acetic acid, and the absorbance at 405 nm was measured in a micro- 
plate reader. These experiments were performed 6 times. 
HC Actioity Assays-Thrombin inhibition activity of HC treated 
with elastase or cathepsin G was measured by incubating 2 FM HC 
with 20 nM elastase or 50 nM cathepsin G in 400 ~1. At intervals, 70- 
~1 aliquots were removed and added to a thrombin inhibition assay 
with final concentrations of 1.4 PM HC, 6 nM thrombin, and 2 mg/ 
ml Polybrene (Aldrich). After 10 min, 650 +l of 0.3 mM tosyl-Gly- 
Pro-Arg-n-nitroanilide (Boehringer Mannheim) was added. and hv- 
drolysis &as stopped after 5 min by the addition of acetic acid. For 
some thrombin inhibition assays, reaction conditions were: 800 nM 
HC, 5 nM thrombin, 2 mg/ml bovine serum albumin (Sigma), 0.1 mg/ 
ml Polybrene, reaction time 30 min. Experiments were performed at 
least 3 times and the results averaged. Control experiments demon- 
strated that elastase and cathepsin G present in the HC samples had 
no effect on thrombin activity or substrate hydrolysis. The active HC 
concentration in a sample was calculated from thrombin activity 
measurements. Since the pseudo-first order rate equation for throm- 
bin inhibition by excess HC is k = -In a/t[HC], where a is thrombin 
activity relative to the uninhibited control, t is time, and k is the rate 
constant, then (HC] = -In a/kt. To express inactivation of HC by 
elastase or cathepsin G (HC..,,,,) relative to untreated HC (HC,,,,,,J, 
k and t were treated as constants so that [HC],,,,,,/[HC],,,,,,, = In 
asampdn aconIro~. These calculations are based on the assumption that 
elastase and cathepsin G affect the concentration of active HC but 
do not affect the rate constant for thrombin inhibition. For digests 
in the presence of heparin or dermatan sulfate, HC was incubated 
with neutrophil proteinases for various times, then 2 aliquots were 
removed and 1) added to the thrombin inhibition assay or 2) added 
to 1% SDS for denaturation and SDS-PAGE. These experiments 
were performed 3 times. 
Additional experiments with cathepsin G involved 500 nM HC 
treated with 500 nM cathepsin G in 400 ~1. At intervals of lo-50 s, 
70-~1 aliquots were removed and added to a thrombin inhibition assay 
with final concentrations of 350 nM HC, 400 nM thrombin, 2 mg/ml 
bovine serum albumin, and 10 fig/ml heparin in 100 ~1. After 5 min, 
200 ~1 of S-2302 (Kabi) was added and hydrolysis was terminated 
after 50 s by the addition of 30 ~1 of 50% acetic acid. The 5-min 
incubation allowed complete reaction between thrombin and HC so 
that the activity of thrombin was linearly related to the concentration 
of active HC. The proportion of HC inactivated by cathepsin G 
(sample) was expressed relative to HC not treated with cathepsin G 
(control): IHCI,,,,I,/IHCI,,,,,.I = (1 - aLmnd(l - aLtrml. where a is 
thrombin &t&y relative to thrombin in- the absence of HC and 
(1 - a) is inhibition activity. These experiments were performed 6 
times. 
Electrophoresis-SDS-polyacrylamide gel electrophoresis (SDS- 
PAGE) was performed in 10% slab gels (22) without chemical reduc- 
tion of samples, with Rainbow molecular weight markers (Amersham 
Corp.). The apparent relative molecular weights of HC and its deriv- 
atives were higher than expected; calculated molecular weights were 
normalized to a molecular weight of 66,000 for native HC (23). The 
possibility of additional proteolysis after addition of SDS was ruled 
out bv the observation that ohenvlmethvlsulfonvl fluoride (PMSF) 
added prior to SDS did not aiter the rest&. - 
Heat Stability Assays-HC (7.6 pM or 0.5 mg/ml) was incubated 
with 76 nM elastase for 1 h or with 76 nM cathepsin G for 3 h 
(conditions under which thrombin inhibition activity was completely 
lost) and then treated with 0.1 mM PMSF. A 500-~1 sample was 
placed in a 58 “C water bath; 50-~1 samples were removed at intervals 
and centrifuged, and protein remainini in solution was assayed using 
a Coomassie Blue G-250 dve-binding assay (Pierce Chemical Co.). 
The results of 2-3 experiments were averaged. 
Preparation of Bands II and III-HC (2 pM) was incubated with 
20 nM elastase for 12 min to produce band II and for 40 min to 
produce band III; HC was incubated with 50 nM cathepsin G for 50 
min (band II) and 4 h (band III). PMSF was added (0.5 mM) to stop 
proteolysis. Following dialysis, samples were analyzed by SDS-PAGE, 
and the Pierce dye-binding assay was used to measure protein content 
(115-130 fig/ml) with HC as a standard. The molarity of the HC 
fragments was calculated from the protein content and apparent 
molecular weight in SDS-PAGE. AsSays for HC activity u&d the 
following conditions: for thrombin inhibition assays: 500 nM HC (or 
HC fragment), 5 nM thrombin, 2 mg/ml bovine serum albumin, 
reaction time 30 min; for heparin cofactor assays: 100 nM HC, 5 nM 
thrombin, 2 mg/ml bovine serum albumin, 10 @g/ml heparin, reaction 
time 10 s; for dermatan sulfate cofactor assays: 100 mM HC, 5 nM 
thrombin, 2 mg/ml bovine serum albumin, 10 pg/ml dermatan sulfate, 
reaction time 1 min. Active HC concentrations were determined as 
described under “HC activity assays.” The entire experiment was 
performed twice, and HC activity assays were performed 3 times. 
Protein Sequencing-Samples contained 2 KM HC digested with 20 
nM elastase (35 min) or 50 nM cathepsin G (2 h) and were treated 
with 1 mM PMSF and dialyzed against 5% acetic acid before seauence 
analysis. Digests were analyzed by the Protein Chemistry Laboratory 
of the University of North Carolina at Chapel Hill on an Applied 
Biosystems 475A protein sequencer. 
RESULTS 
Proteinase Inhibition-Inhibition of amidolytic activity of 
neutrophil elastase and cathepsin G by HC was investigated 
using chromogenic substrates for each proteinase. Minimal 
inhibition of elastase was detected (50% inhibition of 25 nM 
elastase by 7 PM HC) and was not further characterized. In 
contrast, HC inhibited cathepsin G with a second-order rate 
constant of 6.0 X lo6 M-’ min-’ (Table I). Assuming a plasma 
concentration of 1 ELM for HC, this translates to a half-time 
for cathepsin G inhibition of 10 s (t,,* = l/k+i[HC]), which 
may have relevance in uiuo (24). The first-order dissociation 
rate constant for inhibition was also determined: 1.0 x 10d3 
min-’ (equivalent to a half-life of about 11 h). Heparin and 
dermatan sulfate decreased the inhibition rate constant 
slightly and increased the dissociation rate constant, indicat- 
ing less stable inhibition (Table I). A bimolecular complex 
containing HC and cathepsin G was not visible by SDS- 
PAGE. However, during gel filtration of mixtures of HC and 
cathepsin G on Sephacryl S-200, cathepsin G activity eluted 
with the HC peak (not shown). 
Inactivation of HC-Both neutrophil elastase and cathepsin 
G at catalytic concentrations inactivated HC, as measured by 
loss of thrombin inhibition activity (Fig. 1). Neutrophil elas- 
TABLE I 
Inhibition of cathepsin G by heparin cofactor II 
Addition k r, k-1 
None 
Heparin (50 &ml) 
10-e M-’ min-’ IO” min-’ 
6.0 1.0 
4.2 6.4 
Dermatan &l&e (50 pi/ml) 4.7 3.1 
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FK;. 1. Inactivation of heparin cofactor II by neutrophil 
proteinases. HC (2 PM) was incubated with 20 nM neutrophil 
elastase (m), or 50 nM cathepsin G (A), or without proteinase (O), 
and then assayed for thrombin inhibition activity. Data are expressed 
as HC activity relative to the control sample at zero time. 
I 
1 2 3 4 5 6 7 
TIME (h) 
FIG. 2. Heat stability of heparin cofactor II. HC (O), HC 
inactivated by neutrophil elastase (B), and HC inactivated by cathep- 
sin G (A) were incubated at 58 “C and then assayed for protein 
remaining in solution. No correction was made for evaporation. 
tase was more effective than cathepsin G, since a smaller 
amount of elastase was able to inactivate HC in a shorter 
period of time. This may be partially due to inhibition of 
cathepsin G, but not elastase, by HC. 
Since other members of the serpin family of proteins exhibit 
a dramatic increase in heat stability following limited prote- 
olysis (25), the heat stability of HC was investigated. Native 
HC precipitated from solution when incubated at 58 “C (Fig. 
2). When HC was treated with elastase or cathepsin G until 
no thrombin inhibition activity remained, HC was stable in 
solution at 58°C. 
The two proteinases generated HC derivatives of similar 
mobility in SDS-PAGE. During the time course of HC inac- 
tivation, two major degradation products were observed, the 
apparent molecular weights of these were: 58,000 (“band II”) 
and 48,000 (“band III”), compared to native HC (66,000) (Fig. 
3A). Band II appeared first and was converted to band III 
over time. Extended incubation of HC (up to 53 h) with 
elastase did not produce additional degradation of band III; 
however, incubation with cathepsin G produced multiple 
lower molecular weight bands and material migrating with 
the dye front in SDS-PAGE (not shown). These results sug- 
gest that while the two enzymes generate HC fragments by 
proteolysis at or near the same sites initially, the ultimate 
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FIG. 3. Activity of bands II and III derived from heparin 
cofactor II. HC was incubated with neutrophil elastase and cathep- 
sin G to produce bands II and III as described under “Experimental 
Procedures.” Samples were analyzed by SDS-PAGE (A) and assayed 
for thrombin inhibition activity (B). Lane a, HC control. Lane b, HC 
digested with elastase (band II). Lane c, HC digested with elastase 
(band III). Lane d, HC digested with cathepsin G (band II). Lane e, 
HC digested with cathepsin G (band III). The antithrombin (@, 
heparin cofactor (m) and dermatan sulfate (B) cofactor activities of 
preparations b-e are expressed relative to the HC control (sample a). 
products of proteolysis by neutrophil elastase or cathepsin G 
are different. 
Preliminary observations suggested that HC digests con- 
taining band II retained some thrombin inhibition activity. 
This was further quantified by timed incubation of HC with 
neutrophil elastase and cathepsin G to prepare HC digests 
enriched in band II or III, followed by assays for thrombin 
inhibition activity in the presence and absence of glycosami- 
noglycan cofactors. As shown in Fig. 3B, in preparations 
where band II predominated, significant thrombin inhibition 
activity was retained. Cathepsin G inhibition activity was also 
present in band II preparations (not shown). After prolonged 
digestion, where band III predominated, thrombin inhibition 
activity was almost completely abolished. A comparison of 
residual HC inhibition activity in the presence and absence 
of cofactors showed that elastase and cathepsin G destroyed 
the reactive site of HC and not just the cofactor binding site. 
Further evidence for the presence of an intact reactive site 
for thrombin inhibition in band II preparations was obtained 
by incubating these preparations with thrombin, and visual- 
izing higher molecular weight complexes in SDS-PAGE (not 
shown). 
Amino acid sequence analysis was performed on HC-pro- 
teinase digests to identify sites of proteolysis by neutrophil 
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TABLE II 
Amino-terminal sequences of heparin cofactor II digested with neutrophil elastase and cathepsin G 
Cycle 1 2 3 4 5 6 I 8 
Elastase Gly’ (142)” Ser (28) LYS (35) Gly (98) Pro (65) Leu (65) Asp (30) Gln (31) 
Asp= (21) Phe (129) His (4) LYS (22) Glu (29) Asn (29) Thr (9) Val (95) 
PheG7 (103) Ser Glu (26) Asp (41) Asp (46) Asp (65) Ty9 (33) Ile (118) 
Gly4” Phe Met (44) Pro (32) Leu’ (36) Ser (7) Thr Gln 
Cathepsin G Glyl (109) Ser (20) LYS (78) Gly (75) Pro (44) Leu (89) Asp (21) Gln (42) 
PheG7 (45) Ser Glu (20) Asp (14) Asp (17) Asp (20) Tyr (15) Ile (42) 
Gly”O Phe (104) Met (32) Pro (25) Leu (29) Ser (4) Thr (29) Gln 
’ Numbers in parentheses denote picomoles recovered. Note that in some cases. the same residue is derived 
from more than one sequence. 
’ TyrT3 and Tyr” are sulfated in native HC (34). 
‘The reactive site PI-P,’ bond is Leu’4’-Ser (26). 
L 
I 
TIME <wad TIME <sea> 
FIG. 4. Inhibition of cathepsin G and inactivation of heparin 
cofactor II by cathepsin G. HC (500 nM) was incubated with 
cathepsin G (500 nM) and aliquots were removed at intervals for 
assays of cathepsin G amidolytic activity and thrombin inhibition 
activity as described under “Experimental Procedures.” A, cathepsin 
G inhibition and HC inactivation. Cathepsin G activity (A) is ex- 
pressed relative to cathepsin G activity in the absence of HC, and 
HC activity (0) is expressed relative to HC activity in the absence of 
cathepsin G. B, replot of cathepsin G inhibition and HC inactivation 
data from A for determination of second-order rate constants. Ca- 
thepsin G activity (A); HC activity (0). 
elastase and cathepsin G. In analyses of mixtures of bands II 
and III, multiple residues were obtained at each cycle. In both 
neutrophil elastase and cathepsin G digests the amino-ter- 
minal sequence, the sequence beginning with Phe67, and the 
sequence beginning with GUYED” were identified. Neither pro- 
teinase cleaved the reactive site bond: Leu444-Ser (26). No 
other sequences were unambiguously identified in cathepsin 
G digests, but elastase digestion also produced a new amino- 
terminal sequence beginning with Asp39 (Table II). 
Relationship between Cathepsin G Inhibition and HC Znac- 
tiuation-In order to directly compare HC inactivation with 
cathepsin G inhibition, both reactions were followed under 
identical conditions of time and concentration. As shown in 
Fig. 4A, both inhibition and inactivation occurred in the same 
interval. The calculated second-order rate constants were 6.2 
X lo6 M-’ min-’ for cathepsin G inhibition and 1.6 x lo6 M-r 
min-’ for HC inactivation. These rate constants are probably 
overestimations since the reactions are simultaneous: some 
apparent cathepsin G inhibition might result from the reac- 
tion in which HC is inactivated, and some apparent inability 
of HC to inhibit thrombin might be the result of cathepsin G 
inhibition. This was also demonstrated by intercepts of 
greater than unity in the replot (Fig. 4B). When the data 
were normalized to give intercepts of unity, the rate constants 
became 3.6 X lo6 M-’ min-’ for cathepsin G inhibition and 
1.4 X lo6 M-r min-1 for HC inactivation. Under the same 
reaction conditions, the dissociation rate constant for cathep- 
I 
FIG. 5. Effect of glycosaminoglycans on heparin cofactor II 
inactivation. HC (2 NM) was incubated with 20 nM neutrophil 
elastase (a) for 20 min or with 50 nM cathepsin G (A) for 60 min in 
the presence of varying concentrations of heparin or dermatan sulfate. 
A, inactivation of HC in the presence of heparin. B, inactivation of 
HC in the presence of dermatan sulfate. Data for A and 8 are 
expressed relative to a control sample of HC inactivated by proteinase 
in the absence of glycosaminoglycan. C, proteinase activity in the 
presence of heparin. D, proteinase activity in the presence of derma- 
tan sulfate. Data for C and D are expressed as proteinase activity, 
measured as chromogenic peptide substrate hydrolysis, relative to a 
control in the absence of glycosaminoglycan. The same proteinase 
concentrations were used for HC inactivation assays (A, B) and for 
substrate hydrolysis experiments (C, D). 
sin G inhibition was 3.5 X 10e3 min-’ (half-life of 3.3 h; not 
shown), thus demonstrating that inactivation of HC by ca- 
thepsin G did not occur following dissociation of cathepsin G. 
The stability of cathepsin G inhibition by HC was further 
demonstrated by the inability of excess thrombin to promote 
cathepsin G dissociation from HC (not shown). The possibil- 
ity that neutrophil elastase contaminants in the cathepsin G 
preparation were responsible for HC inactivation was dis- 
counted hy demonstrating that 125 nM al-proteinase inhibitor 
(titrated with elastase) added to 500 nM cathepsin G did not 
affect cathepsin G inhibition, HC inactivation by cathepsin 
G, or HC proteolysis by cathepsin G (not shown). 
Effect of Heparin and Dermatan Sulfate on HC Znactiua- 
tion-Because glycosaminoglycans such as heparin and der- 
matan sulfate alter the rate of thrombin inhibition by HC, 
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and because heparin has been reported to accelerate the rate 
of inactivation of antithrombin III by elastase (8), the effect 
of glycosaminoglycans on the inactivation of HC was inves- 
tigated. Following incubation of HC with neutrophil elastase 
or cathepsin G in the presence of varying amounts of heparin 
or dermatan sulfate (0.1 Kg/ml to 3 mg/ml), thrombin inhi- 
bition was measured. Increasing heparin concentrations ini- 
tially afforded slight protection of HC from inactivation by 
neutrophil proteinases, but above about 10 fig/ml, heparin 
accelerated HC inactivation (Fig. 5A). In contrast, dermatan 
sulfate at all concentrations caused only a slight increase in 
the rate of HC inactivation (Fig. 5B). The effect of glycosa- 
minoglycans on HC inactivation was not correlated with the 
effect of glycosaminoglycans on the activity of each proteinase 
as assayed by small chromogenic substrates. For example, HC 
inactivation was increased at high concentrations of dermatan 
sulfate, where both elastase and cathepsin G activities were 
depressed (Fig. 50). Furthermore, the concentration depend- 
ence of the heparin effect on HC inactivation was similar for 
neutrophil elastase and cathepsin G, even though the amidol- 
ytic activity of these enzymes responded differently to various 
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FIG. 6. Proteolysis and inactivation of heparin cofactor II 
in the presence of glycosaminoglycans. HC (2 pM) was digested 
with 20 nM neutrophil elastase for 20 min or with 100 nM cathepsin 
G for 25 min in the presence or absence of 50 pg/ml heparin or 100 
pg/ml dermatan sulfate. Samples were analyzed by SDS-PAGE (A) 
and assays for thrombin inhibition activity (B). Lane a, HC control; 
lane b, HC and elastase; lane c, HC and elastase with heparin; lane d, 
HC and elastase with dermatan sulfate; lane e, HC and cathepsin G; 
lane f, HC and cathepsin G with heparin; lane g, HC and cathepsin 
G with dermatan sulfate. 
The inactivation of HC at high concentrations of heparin 
and dermatan sulfate resulted in altered patterns of degrada- 
tion of HC protein as visualized by SDS-PAGE (Fig. 6). When 
heparin was included, a band similar to band III predomi- 
nated, and HC activity was greatly reduced. When dermatan 
sulfate was included, HC activity was reduced, although pro- 
teolysis appeared to be diminished relative to controls in the 
absence of glycosaminoglycan. A band similar to band II was 
apparent in samples containing dermatan sulfate, but this 
raises the possibility that this species was not identical to 
band II, which retains inhibitory activity. It is possible that 
glycosaminoglycans alter the susceptibility of HC to proteol- 
ysis such that inactivation at the reactive site can occur 
without extensive proteolysis in the amino-terminal region of 
the HC molecule. 
DISCUSSION 
This study was undertaken to determine whether HC in- 
hibits the hydrolytic activity of two major neutrophil protein- 
ases or is inactivated by them. Our results demonstrate that 
HC inhibits cathepsin G under physiological conditions, but 
that both cathepsin G and elastase can proteolyze and destroy 
the thrombin inhibition activity of HC. The inhibition of 
cathepsin G by HC might be important in uiuo as a supple- 
ment to cY1-antichymotrypsin inhibition of cathepsin G (27). 
The less stable inhibition obtained in the presence of glyco- 
saminoglycans most likely reflects binding of the proteinase 
to the polyanion, also noted by others (28). The absence of a 
covalent SDS-stable HC-cathepsin G complex is similar to 
results with HC-chymotrypsin (11) and al-proteinase inhibi- 
tor-trypsin (29). However, the failure to detect the sequence 
beginning with Ser445 suggests that cathepsin G does not 
actually hydrolyze the Leu444-Ser bond. Our inhibition meas- 
urements differ significantly from those of a previous study 
which reported an inhibition rate constant of only 1.4 X lo4 
Mm1 min-‘, possibly due to different reaction temperatures 
(30). The mechanism of cathepsin G inhibition is discussed 
further below. 
The inactivation of HC by neutrophil elastase or cathepsin 
G was accompanied by increased heat stability, which is 
consistent with a conformational change caused by proteolytic 
cleavage of the reactive site peptide loop of HC. This is the 
first report of the heat stability phenomenon in HC, which 
has been well documented for other members of the serpin 
family (25, 31). Proteolysis of the reactive site peptide loop 
renders other serpins inactive as proteinase inhibitors (31). 
Sequence data provided strong evidence that the inactivation 
of HC by neutrophil elastase and cathepsin G was accom- 
plished by proteolysis of the reactive site loop at Val*“‘-Gly 
(the Ps-Ps bond in the nomenclature of Schechter and Berger 
(32)). 
Both neutrophil elastase and cathepsin G also hydrolyze 
HC near the amino terminus, at the Ile”‘-Phe bond, as shown 
by sequence analysis. We conclude that this cleavage produces 
band II in SDS-PAGE, which retains thrombin inhibition 
activity. This is not unexpected since the reactive site of HC 
is located near the carboxyl terminus of HC (26). We have 
previously identified a degraded form of HC (with an amino 
terminus corresponding to Asn4’) that contains an intact 
reactive site (16). The results of HC activity assays and SDS- 
PAGE analysis indicate that the Ile66-Phe bond is cleaved 
before the Va14”g-Gly bond. Neutrophil elastase and cathepsin 
G generate the same proteolytic fragments from HC. HC 
differs from antithrombin III and a2-antiplasmin in that 
proteolysis of HC by neutrophil proteinases initially generates 
a degraded form of the inhibitor that retains activity. Only 
Heparin Cofactor II and Neutrophil Elastase and Cathepsin G 6097 
Cl inhibitor appears to share this feature (6). 
The effect of heparin and dermatan sulfate on the inacti- 
vation of HC by neutrophil proteinases is not correlated with 
the effect of the glycosaminoglycan on proteinase activity (as 
assessed with small chromogenic substrates) but is consistent 
with glycosaminoglycan binding to HC to alter its suscepti- 
bility to proteolysis. The accelerated inactivation of HC in 
the presence of high concentrations of glycosaminoglycans 
might involve a ternary complex consisting of glycosamino- 
glycan, inhibitor, and proteinase (similar to the ternary com- 
plex formed during thrombin inhibition by HC and glycosa- 
minoglycan (33)). The greater effect of heparin compared to 
dermatan sulfate parallels the tighter binding of heparin to 
HC (9), but might also reflect a different binding mechanism. 
Our data show that the heparin effect at least is markedly 
concentration-dependent. The protective effect of heparin at 
low concentrations is at present unexplained, although it is 
possible that this reflects a heparin-induced decrease in pro- 
teinase activity, which was observed with elastase but which 
was not detected when cathepsin G was assayed with a syn- 
thetic peptide substrate. Sie et al. (13) reported that 1 pg/ml 
heparin protected HC from inactivation by neutrophil lysates, 
while 10 pg/ml dermatan sulfate had no effect; higher glycos- 
aminoglycan concentrations were not tested. Our results ex- 
tend the observations of Sie et al. (13) and demonstrate that 
HC shares with antithrombin III the property of heparin- 
accelerated inactivation by neutrophil elastase. The results of 
SDS-PAGE indicate that glycosaminoglycans do not simply 
increase the rate of conversion of HC to band II and then 
band III, but probably promote proteolysis near the reactive 
site, thus rendering HC inactive with respect to thrombin 
inhibition. 
terminal portion of HC (lo).’ The results of this paper dem- 
onstrate that proteolysis at Ile@-Phe occurs without diminish- 
ing proteinase inhibition activity near the carboxyl terminus. 
Although it is not known whether heparin or dermatan sulfate 
influence the production of chemotactic activity, glycosami- 
noglycans might play a role in defining the susceptibility of 
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by HC but also inactivates the inhibitor, there are two possi- 
bilities. One is that the interaction of cathepsin G with the 
Val@‘-Gly bond results in stable inhibition and prevents 
thrombin from reacting at Leu444-Ser. However, this does not 
explain how small amounts of cathepsin G can inactivate a 
large molar excess of HC since the apparent dissociation of 
the HC-cathepsin G complex has a half-time of hours. Nor 
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bition and HC inactivation are different. The second possi- 
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inactivation reactions simultaneously and independently. In- 
hibition of cathepsin G probably occurs at the reactive site of 
HC (as with the similar proteinase chymotrypsin (ll)), al- 
though the typical serpin complex, which is SDS-stable (24) 
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hydrolyzed. During the course of the cathepsin G inhibition 
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nus to further destroy HC inhibition activity by cleaving the 
Va1439-Gly bond. In the presence of a large molar excess of 
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available to participate in HC inactivation. The second pos- 
sibility also explains how cathepsin G can remain inhibited 
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(cleavage at Va1439). 
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